|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Lung cancer in never smokers: molecular profiles and therapeutic implications 显示文摘 | Rudin CM Avila-Tang E Harris CC | 2009 | Clin Cancer Res2009，15，18： | 1 |
| 2 | A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topoteean in relapsed small cell lung cancer显示文摘 | Paik PK Rudin CM Pietanza MC | 2011 | Lung Cancer2011，74，： | 1 |
| 3 | Treatment of SmallCell Lung Cancer:American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline显示文摘 | Rudin CM Ismaila N Hann CL | 2015 | J Clin Oncol2015，33，34： | 1 |
| 4 | Inhibition of glutathione synthesis reverses bcl-2 mediated cisplatin resistance显示文摘 | Yang Z Schumaker LM | 2003 | Cancer Res2003，63，2： | 1 |
| 5 | Epigenetic therapy in non-small- cell lung cancer: targeting DNA methyltransferases and histone deacetylases 显示文摘 | Vendetti FP Rudin CM | 2013 | Expert Opin Biol Ther2013，13，9： | 1 |
| 6 | PhaseⅠtrial of ISIS 5132,an antisense oligonucleotide inhibitor of C-raf-1,administered by 24-hour weekly infusion to patients with advanced cancer显示文摘 | Rudin CM Holmlund J Fleming GF | 2001 | Clin Cancer Res2001，7，： | 1 |
| 7 | Apoptosis and disease: regulation and clinical relevance of programmed cell death显示文摘 | Rudin CM & Thompson CB | 1997 | Annu Rev Med1997，48，： | 1 |
| 8 | Phase 1 trial of hedge- hog pathway inhibitor vismodegib ( GDC-0449 ) in patients with re- fractory, locally advanced or metastatic solid tumors 显示文摘 | LoRusso PM Rudin CM Reddy JC | 2011 | Clin Cancer Res2011，17，8： | 1 |
| 9 | Management of small cell lung cancer; incremental changes but hope for the future 显示文摘 | Hann CL Rudin CM | 2008 | Oncology2008，22，13： | 1 |
| 10 | Expression of Bcl-xl can confer a multodrug resistance phenotype显示文摘 | Minn AJ Rudin CM Boise LH | 1995 | Blood1995，86，5： | 1 |
| 11 | Management of small-cell lung cancer: incremental changes but hope for the future显示文摘 | Harm CL Rudin CM | 2008 | Oncology(Willisto nPark NY)2008，22，13： | 1 |
| 12 | Management of small-cell lung cancer:incremental changes but hope for the future显示文摘 | Hann CL Rudin CM | | 0，，： | 1 |
| 13 | A first-in-human,first-inclass,phase (ph) Ⅰ study of systemic Hedgehog (Hh) pathway antagonist,GDC-0449,in patients (pts) with advanced solid tumors显示文摘 | Lorusso PM Rudin CM Borad MJ | 2008 | J Clin Oncol2008，26，15： | 1 |
| 14 | Inhibition of glugthione synthesis reverses bcl- 2 mediated cisplatin resistance 显示文摘 | Rudin CM Yang Z Schumake LM | 2003 | Cancer Res2003，63，2： | 1 |
| 15 | A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer 显示文摘 | Rudin CM Otterson GA Mauer MA | 2002 | Ann Oneol2002，13，4： | 1 |
| 16 | Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer显示文摘 | Rudin CM Kozloff M Hoffman PC | 2004 | J Clin Oncol2004，22，6： | 1 |
| 17 | Management of small-cell lung cancer:incremental changes but hope for the future显示文摘 | Hann CL Rudin CM | | 0，，： | 1 |
| 18 | A phase Ⅱa study of ABT-263 in patients with relapsed small-cell lung cancer (SCLC)显示文摘 | Rudin CM Oliveira MR Garon EB | 2010 | J Clin Oncol2010，28，15： | 1 |
| 19 | Phase Ⅰ study of G3139,a bcl-2 antisense oligonucleotide,Combined with carboplatin and etoposide in patients with small-cell lung cancer显示文摘 | Rudin CM Kozloff M Hoffman PC | 2004 | Clin Oncol2004，22，6： | 1 |
| 20 | Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picoma- virus, in advanced solid tumors with neuroendocrine features 显示文摘 | Rudin CM Poirier JT Senzer NN | 2011 | Clin Cancer Res2011，17，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员